Dizal (Jiangsu) Pharmaceutical Co. Ltd. A
医疗健康 · 专科与仿制药
Dizal (Jiangsu) Pharmaceutical Co., Ltd., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of oncology and hematologic disorders. Its assets include the ZEGFROVY, for the treatment of solid tumors; Gao Ruizhe to treat hematological malignancy, solid tumors, and immunological diseases; Birelentinib indicated for hematological malignancy; DZD2269, DZD1516, and DZD6008 for solid tumors; and GW5282 for hematological malignancy and solid tumors. Dizal (Jiangsu) Pharmaceutical Co., Ltd. was founded in 2017 and is based in Shanghai, China.
MARKET 市值 22.05B CNY 52W ¥35.73 – ¥86.18
EODHD · Q 2026-03-31 · 同步 2026-07-12
QUALITY PEG — 营收 YoY 58.2%
▲ ROE -106.7% 营业利润率 -38.0% 净利润率 -74.6%